The transaction will add ABL's Liverpool biomanufacturing facility to Pharmaron's business, allowing it to develop CGT products at a commercial scale, it said. The site will provide process research and development, current good manufacturing practice (cGMP) manufacturing, and advanced analytical capabilities for a range of biologics products. The company recently purchased Absorption Systems of Exton, PA, as part of its CGT service platform expansion.

The deal is expected to close in the second quarter of this year.

Rentschler sets up cell and gene therapy center of excellence in U.K.
Contract development and manufacturing organization Rentschler Biopharma has announced that it is establishing a center for excellence for cell and gene...

Private equity firm commits millions to cell and gene therapy
Private equity firm Welsh, Carson, Anderson & Stowe will commit up to $250 million in a strategic partnership with Kiniciti, a newly formed platform...

Bio-Techne invests in China-based cell and gene therapy media company
Bio-Techne has made an initial minority strategic equity investment in Changzhou Eminence Biotechnology. The companies will synergistically work on the...

Cognate, Nucleus Biologics partner on cell, gene therapy media
Contract development and manufacturing organization Cognate BioServices and Nucleus Biologics have partnered to provide custom and commercial medias and...

FDA issues COVID-19 guidance for cell and gene therapy manufacturers
The U.S. Food and Drug Administration (FDA) published new guidance this week regarding manufacturing consideration for cell and gene therapy products...